Capital Investment Advisory Services LLC Acquires 18,028 Shares of Bristol Myers Squibb Company $BMY

Capital Investment Advisory Services LLC raised its holdings in shares of Bristol Myers Squibb Company (NYSE:BMY) by 110.6% in the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 34,330 shares of the biopharmaceutical company’s stock after acquiring an additional 18,028 shares during the period. Capital Investment Advisory Services LLC’s holdings in Bristol Myers Squibb were worth $1,852,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently modified their holdings of BMY. Darwin Wealth Management LLC bought a new stake in shares of Bristol Myers Squibb in the 2nd quarter valued at about $25,000. Harbor Capital Advisors Inc. increased its stake in shares of Bristol Myers Squibb by 107.2% in the 3rd quarter. Harbor Capital Advisors Inc. now owns 605 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 313 shares during the last quarter. KERR FINANCIAL PLANNING Corp bought a new stake in shares of Bristol Myers Squibb in the 3rd quarter valued at about $35,000. JPL Wealth Management LLC bought a new stake in shares of Bristol Myers Squibb in the 3rd quarter valued at about $36,000. Finally, Total Investment Management Inc. bought a new stake in shares of Bristol Myers Squibb in the 2nd quarter valued at about $38,000. 76.41% of the stock is owned by institutional investors.

Insider Transactions at Bristol Myers Squibb

In other Bristol Myers Squibb news, EVP David V. Elkins sold 30,000 shares of the firm’s stock in a transaction on Wednesday, April 1st. The stock was sold at an average price of $61.67, for a total transaction of $1,850,100.00. Following the completion of the sale, the executive vice president owned 159,248 shares of the company’s stock, valued at $9,820,824.16. This trade represents a 15.85% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.09% of the stock is owned by corporate insiders.

Bristol Myers Squibb Trading Up 0.5%

Bristol Myers Squibb stock opened at $59.48 on Friday. The firm has a 50-day moving average of $59.70 and a 200-day moving average of $53.02. Bristol Myers Squibb Company has a one year low of $42.52 and a one year high of $62.89. The company has a debt-to-equity ratio of 2.32, a current ratio of 1.26 and a quick ratio of 1.14. The company has a market cap of $121.45 billion, a price-to-earnings ratio of 17.24, a P/E/G ratio of 0.17 and a beta of 0.27.

Bristol Myers Squibb (NYSE:BMY) last released its earnings results on Thursday, February 5th. The biopharmaceutical company reported $1.26 earnings per share for the quarter, missing the consensus estimate of $1.65 by ($0.39). Bristol Myers Squibb had a net margin of 14.64% and a return on equity of 69.65%. The firm had revenue of $12.50 billion during the quarter, compared to the consensus estimate of $12.24 billion. During the same period in the prior year, the business posted $1.67 earnings per share. Bristol Myers Squibb’s quarterly revenue was up 1.3% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. On average, equities analysts expect that Bristol Myers Squibb Company will post 6.74 earnings per share for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, May 1st. Shareholders of record on Thursday, April 2nd will be issued a dividend of $0.63 per share. The ex-dividend date of this dividend is Thursday, April 2nd. This represents a $2.52 annualized dividend and a yield of 4.2%. Bristol Myers Squibb’s dividend payout ratio (DPR) is currently 73.04%.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on BMY. UBS Group reaffirmed a “buy” rating and issued a $70.00 price target on shares of Bristol Myers Squibb in a research note on Friday, March 6th. Morgan Stanley reissued an “underweight” rating and set a $40.00 target price on shares of Bristol Myers Squibb in a research note on Friday, February 6th. Cantor Fitzgerald increased their target price on Bristol Myers Squibb from $45.00 to $54.00 and gave the stock a “neutral” rating in a research note on Wednesday. Barclays started coverage on Bristol Myers Squibb in a research note on Thursday, February 19th. They set an “overweight” rating and a $75.00 target price for the company. Finally, HSBC increased their target price on Bristol Myers Squibb from $53.00 to $60.00 and gave the stock a “hold” rating in a research note on Tuesday, March 17th. Nine analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $61.71.

Key Bristol Myers Squibb News

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Cobenfy shows commercial traction — 2025 sales of roughly $155M, outpacing peers and supporting upside from label expansion and new indications, which strengthens BMY’s growth outlook. Does Cobenfy Have the Potential to Become a Top Drug for BMY?
• Positive Sentiment: New Oxford BioTherapeutics collaboration to discover next‑gen T‑cell engagers for solid tumors — deal includes upfront, milestones and royalties and validates BMS’s oncology partnering strategy. This could expand pipeline optionality and future revenue streams. Oxford BioTherapeutics Enters Strategic Collaboration with Bristol Myers Squibb to Discover and Develop Next-Generation T-cell Engagers for Solid Tumours
• Positive Sentiment: Guggenheim reaffirmed a “buy” and a $72 price target, supporting optimism among some sell‑side investors about longer-term upside. Guggenheim Reaffirms Buy on BMY
• Neutral Sentiment: Bank of America trimmed its price target slightly (from $68 to $67) but kept a “buy” rating — modest tweak that doesn’t change the positive rating but narrows near‑term upside. BofA Price Target Change
• Neutral Sentiment: BofA note that biopharma names are largely exempt from proposed pharma tariffs — reduces a macro policy risk for large-cap drugmakers like BMY. Biopharma Stocks Largely Exempt From Pharma Tariffs, BofA Says
• Negative Sentiment: Q1 earnings risk — Street previews point to a potential double‑digit drop in Q1 EPS, a near‑term catalyst that could pressure the stock if results miss expectations. Bristol-Myers Squibb Earnings Preview: What to Expect
• Negative Sentiment: Cantor Fitzgerald raised its target from $45 to $54 but reiterated a Neutral rating and flagged a weak Q1 catalyst — the note highlights limited near‑term upside. Cantor Fitzgerald Lifts Bristol Myers (BMY) Price Target but Flags Weak Q1 Catalyst

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.